The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Effects of Metformin on the Gut Microbiota in Obesity and Type 2 Diabetes Mellitus
Open accessAbstract
Metformin is a first-line treatment for type 2 diabetes mellitus (T2DM); however, its underlying mechanism is not fully understood. Gut microbiota affect the development and progression of T2DM. In recent years, an increasing number of studies has focused on the relationship between metformin and gut microbiota, suggesting that metformin might exert part of its hypoglycemic effect through these microbes. However, most of these results were not consistent due to the complex composition of the microbiota, the differences between species, the large variation between individuals, and the differences in experimental design, bringing great obstacle for our better understanding of the effects of metformin on the gut microbiota. Here, we reviewed the published papers concerning about the impacts of metformin on the gut microbiota of mice, rats, and humans with obesity or T2DM, and summarized the changes of gut microbiota composition caused by metformin and the possible underlying hypoglycemic mechanism which is related to gut microbiota. It was found that the proportions of some microbiota, such as phyla Bacteroidetes and Verrucomicrobia and genera Akkermansia, Bacteroides and Escherichia , were significantly affected by metformin in several studies. Metformin may exert part of hypoglycemic effects by altering the gut microbiota in ways that maintain the integrity of the intestinal barrier, promote the production of short-chain fatty acids (SCFAs), regulate bile acid metabolism, and improve glucose homeostasis. Keywords: metformin, gut microbiota, obesity, type 2 diabetes mellitus
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A metagenome-wide association study of gut microbiota in type 2 diabetes
Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., Zhang, W., Guan, Y., Shen, D., et al. (2012) · Nature · doi:10.1038/nature11450 · Cited by 6,762
Cani, P. D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A. M., Delzenne, N. M., & Burcelin, R. (2008) · Diabetes · doi:10.2337/db07-1403 · Cited by 4,819 · cited 1×
“High-fat diet could alter the composition of the gut microbiota in mice and increase the concentration of LPS in mouse plasma, leading to intestinal permeability changes and impaired glucose tolerance.(13) Changes in the gut microbiota under metabolic disease conditions can downregulate connexins and claudins in intes…”
BackgroundEvolution of mammals and their gut microbes
Ley, R. E., Hamady, M., Lozupone, C., Turnbaugh, P. J., Ramey, R. R., Bircher, J. S., Schlegel, M. L., Tucker, T. A., Schrenzel, M. D., Knight, R., et al. (2008) · Science · doi:10.1126/science.1155725 · Cited by 3,747 · cited 1×
“These large numbers of bacteria are mainly from nine phyla, Firmicutes, Bacteroidetes, Actinobacteria, Fusobacteria, Proteobacteria, Verrucomicrobia, Cyanobacteria, Spirochaetes, and VadinBE97, among which Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria account for the majority of human gut microbiota.(8…”
BackgroundGut metagenome in European women with normal, impaired and diabetic glucose control
Karlsson, F. H., Tremaroli, V., Nookaew, I., Bergström, G., Behre, C. J., Fagerberg, B., Nielsen, J., & Bäckhed, F. (2013) · Nature · doi:10.1038/nature12198 · Cited by 3,115
Gut Microbiota in Human Adults with Type 2 Diabetes Differs from Non-Diabetic Adults
Larsen, N., Vogensen, F. K., van den Berg, F. W. J., Nielsen, D. S., Andreasen, A. S., Pedersen, B. K., Al-Soud, W. A., Sørensen, S. J., Hansen, L. H., & Jakobsen, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009085 · Cited by 2,952 · cited 1×
“Larsen et al found differences in the gut microbiota at the phylum level between T2DM patients and normal individuals, eg, the non-T2DM group had a significantly higher proportion of Firmicutes than the T2DM group.(10) Two metagenome-wide association studies involving relatively large populations were conducted in Chi…”
ResultForetz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181 · cited 1×
“The major mechanisms of hypoglycemic action of metformin include inhibiting hepatic gluconeogenesis and reducing hepatic glucose output, increasing glucose uptake and utilization in peripheral tissues (muscle and fat), and improving the energy metabolism in muscle, fat, and liver through the activation of AMP-activate…”
BackgroundGut microbiota and intestinal FXR mediate the clinical benefits of metformin
Sun, L., Xie, C., Wang, G., Wu, Y., Wu, Q., Wang, X., Liu, J., Deng, Y., Xia, J., Chen, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0222-4 · Cited by 1,011
Human Gut Microbiota Changes Reveal the Progression of Glucose Intolerance
Zhang, X., Shen, D., Fang, Z., Jie, Z., Qiu, X., Zhang, C., Chen, Y., & Ji, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071108 · Cited by 946
de la Cuesta-Zuluaga, J., Mueller, N. T., Corrales-Agudelo, V., Velásquez-Mejía, E. P., Carmona, J. A., Abad, J. M., & Escobar, J. S. (2017) · Diabetes Care · doi:10.2337/dc16-1324 · Cited by 704
Zhang, X., Zhao, Y., Xu, J., Xue, Z., Zhang, M., Pang, X., Zhang, X., & Zhao, L. (2015) · Scientific Reports · doi:10.1038/srep14405 · Cited by 630 · cited 2×
“Like in mice, the increase in genus Akkermansia caused by metformin was also found in rats treated with HFD and diabetic rats.(41,45) We found ten studies on the effect of metformin on the gut microbiota in obese or T2DM patients, two of which were conducted in obese patients(50,51) and eight in T2DM patients (Table 3…”
BackgroundResultBauer, P. V., Duca, F. A., Waise, T. M. Z., Rasmussen, B. A., Abraham, M. A., Dranse, H. J., Puri, A., O’Brien, C. A., & Lam, T. K. T. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.019 · Cited by 265
Modulation of the gut microbiota by metformin improves metabolic profiles in aged obese mice
Lee, H., Lee, Y., Kim, J., An, J., Lee, S., Kong, H., Song, Y., Lee, C.-K., & Kim, K. (2018) · Gut Microbes · doi:10.1080/19490976.2017.1405209 · Cited by 203
Are Metformin Doses Used in Murine Cancer Models Clinically Relevant
Chandel, N. S., Avizonis, D., Reczek, C. R., Weinberg, S. E., Menz, S., Neuhaus, R., Christian, S., Haegebarth, A., Algire, C., & Pollak, M. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.03.010 · Cited by 176 · cited 1×
“After oral administration, the half-life of metformin is approximately 3–4 hours, which is inconsistent with the duration of its hypoglycemic effect.(5,6) In addition, intravenous administration of metformin could not improve blood glucose.”
BackgroundBarengolts, E., Green, S. J., Eisenberg, Y., Akbar, A., Reddivari, B., Layden, B. T., Dugas, L., & Chlipala, G. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194171 · Cited by 111
The effects of metformin on gut microbiota and the immune system as research frontiers
Pollak, M. (2017) · Diabetologia · doi:10.1007/s00125-017-4352-x · Cited by 98
Ejtahed, H.-S., Tito, R. Y., Siadat, S.-D., Hasani-Ranjbar, S., Hoseini-Tavassol, Z., Rymenans, L., Verbeke, K., Soroush, A.-R., Raes, J., & Larijani, B. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0826 · Cited by 63
Cited by
Metformin: update on mechanisms of action and repurposing potential
Foretz, M., Guigas, B., & Viollet, B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00833-4 · Cited by 699
Herman, R., Kravos, N. A., Jensterle, M., Janež, A., & Dolžan, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031264 · Cited by 254
Xie, X., Liao, J., Ai, Y., Gao, J., Zhao, J., Qu, F., Xu, C., Zhang, Z., Wen, W., Cui, H., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.748872 · Cited by 37
Metadata
- Authors
- Zhang, Q., & Hu, N.
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2020-12
- Volume
- Volume 13
- Pages
- 5003-5014
- ISSN
- 1178-7007 (ISSN-L)
- OpenAlex
- W3111703679
- Cited by
- 179
- References
- 16
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.